Human CD80 enzyme-linked immunoassay kit
| Specification | 96 Test |
|---|---|
| Sensitivity | 0.08 pg/ml (50 μl)；0.52 pg/ml (10 μl) |
| Standard Curve Range | 1.37~1000 pg/ml |
| Standard Curve Gradient | 7 Points/3 Folds |
| Number of Incubations | 2 |
| Sample Volume | 50 μl/10 μl |
| Type | Fully Ready-to-Use |
| Operation Duration | 120min |
| pg/ml | O.D. | Average | Corrected | |
|---|---|---|---|---|
| 0.00 | 0.0107 | 0.0107 | 0.0107 | |
| 1.37 | 0.0294 | 0.0283 | 0.0289 | 0.0182 |
| 4.12 | 0.0649 | 0.0648 | 0.0649 | 0.0542 |
| 12.35 | 0.1801 | 0.1761 | 0.1781 | 0.1674 |
| 37.04 | 0.5149 | 0.5114 | 0.5132 | 0.5025 |
| 111.11 | 1.3710 | 1.4240 | 1.3975 | 1.3868 |
| 333.33 | 3.0950 | 3.2490 | 3.1720 | 3.1613 |
| 1000.00 | 4.2695 | 4.3810 | 4.3253 | 4.3146 |
Precision
| Intra-assay Precision | Inter-assay Precision | |||||
| Sample Number | S1 | S2 | S3 | S1 | S2 | S3 |
| 22 | 22 | 22 | 6 | 6 | 6 | |
| Average(pg/ml) | 20.9 | 106.6 | 336.5 | 22.2 | 109.1 | 333.8 |
| Standard Deviation | 1.2 | 7.2 | 32.8 | 0.7 | 3.4 | 11.9 |
| Coefficient of Variation(%) | 3.9 | 6.8 | 5.9 | 3.0 | 3.2 | 3.6 |
Intra-assay Precision (Precision within an assay) Three samples of known concentration were tested twenty times on one plate to assess intra-assay precision.
Inter-assay Precision (Precision between assays) Three samples of known concentration were tested six times on one plate to assess intra-assay precision.
Spike Recovery
The spike recovery was evaluated by spiking 3 levels of human B7-1/CD80 into health human serum sample. The un-spiked serum was used as blank in this experiment.
The recovery ranged from 81% to 111% with an overall mean recovery of 99%.
Sample Values
| Sample Matrix | Sample Evaluated | Range (pg/ml) | Detectable (%) | Mean of Detectable (pg/ml) |
|---|---|---|---|---|
| Serum | 30 | 17.39-112.32 | 100 | 70.39 |
Serum/Plasma – Thirty samples from apparently healthy volunteers were evaluated for the presence of B7-1/CD80 in this assay. No medical histories were available for the donors.
Product Data Sheet
Background: CD80
B7-1 and B7-2, together with their receptors CD28 and CTLA-4, constitute one of the dominant co-stimulatory pathways that regulate T- and B-cell responses. Although both CTLA-4 and CD28 can bind to the same ligands, CTLA-4 binds to B7-1 and B7-2 with a 20‑100 fold higher affinity than CD28 and is involved in the down‑regulation of the immune response. B7-1 is expressed on activated B cells, activated T cells, and macrophages. B7-2 is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B7-2 is expressed at low levels on monocytes and can be up‑regulated through Interferon gamma. B7-1 and B7-2 are both members of the Immunoglobulin superfamily. Human B7-1 is a 288 amino acid (aa) protein containing a 34 aa signal peptide, a 208 aa extracellular domain, a 21 aa transmembrane domain, and a 25 aa cytoplasmic domain. Human B7-1 and B7-2 share 26% aa sequenceidentity. Human and mouse B7-1 share 44% aa sequenceidentity. However, it has been observed that both human and mouse B7-1 and B7-2 can bind to either human or mouse CD28 and CTLA-4, suggesting that there are conserved amino acids which form the B7-1/B7-2/CD28/CTLA-4 critical binding sites.
